Referências Complementares


1: Pereira, WV. Leucemia Mielóide Aguda na Infância e Adolescência. In: Zago A; Falcão RP; Pasquini R. (Org.). Hematologia: Fundamentos e prática. Ateneu, 2001, p. 459-476.

2: Weinstein HJ. Acute Myeloid Leukemia. In: Childhood Leukemias, Edit by  Pui CH. 1999, p. 322-335.

3: Margolis David, Casper James T. Allogeneic transplantation for Acute Myeloid Leukemia in children. In: Thomas Hematopoietic Cell Transplantation, Edit by Blume KG, Forman SJ, Appelbaum FR. Third Edition, 2004, p. 1040-1054.
 

5:  Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G; Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002 Aug;118(2):385-400.
 

6:  Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S,Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ.  Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996 Jun 15;87(12):4979-89.
 

7:  Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bokkerink JP, Tissing WJ, Samuelsson U, Feingold J, Creutzig U, Kaspers GJ.  Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003 May 15;101(10):3868-71.
 

8:  Wells RJ, Arthur DC, Srivastava A, Heerema NA, Le Beau M, Alonzo TA, Buxton AB, Woods WG, Howells WB, Benjamin DR, Betcher DL, Buckley JD, Feig SA, Kim T, Odom LF, Ruymann FB, Smithson WA, Tannous R, Whitt JK, Wolff L, Tjoa T, Lampkin BC.  Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia. 2002 Apr;16(4):601-7.
 

9:  Pui CH, Raimondi SC, Srivastava DK, Tong X, Behm FG, Razzouk B, Rubnitz JE, Sandlund JT, Evans WE, Ribeiro R. Prognostic factors in infants with acute myeloid leukemia. Leukemia. 2000 Apr;14(4):684-7.
 

10:  Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jurgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H.  Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001 May 15;19(10):2705-13.
 

11:  Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, Lange BJ, Kobrinsky NL; Children's Cancer Group.  A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001 Jan 1;97(1):56-62.
 

12:  Chown SR, Marks DI, Cornish JM, Pamphilon DH, Potter MN, Steward CG, Oakhill A. Unrelated donor bone marrow transplantation in children and young adults with acute myeloid leukaemia in remission. Br J Haematol. 1997 Oct;99(1):36-40.
 

13: Beverly J  Lang. Acute Myeloid leukemia in children and adolescents. In: Edward S Henderson at al. Leukemia. Saunders, 7th Edition, 2002, p. 519.